Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company focused on developing innovative therapies for ...

Perspective AI emerged from stealth today to announce a $4 million seed funding round led by Village Global, Array Ventures, Honeystone VC, Recursive Ventures, Darkmode VC, and prominent angel ...

I have had the great privilege of serving my local health system as Medical Director for Home Hospice. Every week I sit in a ...

"What is a tumor?" This is the fundamental question to answer if we want to treat cancer effectively. Our vision of cancer ...

In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...

Capital Markets increased its price target on Perspective Therapeutics Inc (NYSE:CATX) shares to $20.00, up from the previous $15.00, while maintaining a Buy rating on the stock. The $259.2 million ...

CIA’s Master’s in Culinary Therapeutics. Hyde Park, NY, January 27, 2025 – CIA has introduced a first-of-its-kind Culinary ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Perspective Therapeutics (CATX – Research ...

Perspective Therapeutics Inc (CATX) stock saw a modest uptick, ending the day at $4.01 which represents a slight increase of $0.38 or 10.47% from the prior close of $3.63. The stock opened at $3.64 ...

In a report released today, Nicole Germino from Truist Financial maintained a Buy rating on Perspective Therapeutics (CATX – Research Report).

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a report released ...

Perspective Therapeutics shares interim results for [212Pb]VMT-α-NET trial, showing promising safety, stable disease cases, ...